BI 765845
Alternative Names: BI-765845Latest Information Update: 08 Jan 2024
At a glance
- Originator Boehringer Ingelheim
- Class Anti-ischaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Myocardial infarction
Most Recent Events
- 17 Dec 2023 Boehringer Ingelheim completes a phase I trial in Myocardial infarction (In volunteers) in Japan (IV) (NCT06139341)
- 24 Nov 2023 Phase-II clinical trials in Myocardial infarction (In adults, In the elderly) in Germany (IV) (NCT06139328)
- 24 Nov 2023 Phase-II clinical trials in Myocardial infarction (In adults, In the elderly) in Spain (IV) (NCT06139328)